Select Your Location:
Global
France
Italy

memo inHaematology EHA2024 Congress Report

Tag: Hematologic Malignancies

BeiGene is advancing a hematologic malignancy pipeline consisting of novel oral small molecules and monoclonal antibodies. Among these are zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor and BGB-11417, a BCL2 inhibitor, both for the treatment of various B-cell malignancies.

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

Slide-Kit
26 May 2025
Please login or register to access the download

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Network Meta-Analysis (NMA) methodology.

Video
26 May 2025

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Matching Adjusted Indirect Comparison (MAIC) methodology.

Video
26 May 2025

A summary of 12 studies from ASH 2024 addressing the use of BTK inhibitors, Bcl-2 inhibitors, BTK degraders, and other emerging therapies for B-cell malignancies.

Slide-Kit
26 May 2025
Please login or register to access the download

ASPEN (NCT03053440) is an open-label, randomized, Phase 3 study comparing the safety, efficacy and clinical benefit of zanubrutinib versus ibrutinib in activating MYD88 mutated (MYD88MUT) Waldenström’s macroglobulinemia (WM) patients. In an additional cohort, the efficacy and safety of zanubrutinib in MYD88 wild-type (MYD88WT) WM patients were evaluated.

Reading
23 May 2025